Clinical Trial

A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

Name: A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia — clinical trial record (NCT07743112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.

Trial Details

NCT Number	NCT07743112
Lead Sponsor	Maxinovel Pty., Ltd.
Conditions	Acute Myeloid Leukemia
Enrollment	43 participants
Start Date	2025-09-05
Primary Completion	2027-09-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-03